共 50 条
- [21] A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus weekly gemcitabine (Gem) in patients (pts) with advanced solid tumors: preliminary resultsJOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)Patnaik, A.Pipas, M.Rosen, L. S.Wood, L.Phipps, K.Mulay, M.Garay, C.Korc, M.Sarantopoulos, J.
- [22] A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus FOLFOX4 in patients (pts) with advanced solid tumors: Preliminary resultsJOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)Limentani, S.Just, R.Purdham, A.Mulay, M.Bair, A.Tamby, J. F.Chap, L. I.Rosen, L. S.
- [23] Dose escalation of a phase 1b/2 study of modakafusp alfa, an immune-targeting attenuated cytokine, in patients (pts) with metastatic solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Johnson, Melissa LynneAbdul-Karim, RaghadSommerhalder, DavidHafez, NavidWang, ShiningLi, CherylLiu, YuyinYang, LiliCollins, SabrinaParot, XavierStrauss, James F.
- [24] Tolerability, efficacy and recommended phase II dose (RP2D) of tepotinib plus gefitinib in Asian patients with c-Met-positive/EGFR-mutant NSCLC: Phase Ib data.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Wu, Yi-LongSoo, Ross A.Kim, Dong-WanYang, James Chih-HsinStammberger, Uz M.Chen, WenfengJohne, AndreasPark, Keunchil
- [25] Results of 2 phase I studies of intravenous (iv) pelitrexol (AG2037), a glycinamide ribonucleotide formyltransferase (GARFT) inhibitor, in patients (pts) with solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 213S - 213SRobert, FGarrett, CDinwoodie, WRSullivan, DMBishop, MAmantea, MZhang, MReich, SD
- [26] Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)-SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation resultsANNALS OF ONCOLOGY, 2024, 35 : S518 - S518Moreno Garcia, V.Oh, D-Y.Ryu, M. H.Calvo, E.Garralda, E.Chung, W-P.Bai, L-Y.Rojas Laimito, K. I.Yildirim, O.Masciari, S.Mi, G.Wang, L.Kanlikilicer, P.Buday, B.Rharbaoui, F.Abbadessa, G.Dumbrava, E. E.
- [27] Phase II dose optimization with EZH2/EZH1 inhibitor tulmimetostat in patients (pts) with advanced solid tumors or hematologic malignanciesJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Oaknin, AnaBanda, KalyanDrescher, CharlesRibrag, VincentKindler, Hedy L.Walter, Harriet S.Tewari, AlokPons-Tostivint, ElvireLakhani, Nehal J.Harvey, R. DonaldSullivan, Ryan J.Zinzani, Pier LuigiMartin, Antonio GonzalezEberst, LaurianeSanchez, Luis MansoThakur, AnjaliKann, LennartReddy, ArchanaFaulhaber, NicolaDuska, Linda
- [28] Biomarker results supporting selection of RP2D from a phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Daemen, AnneleenPankov, AleksandrBarkund, ShravaniZhou, HaiyingDuff, MaureenJohnson, AnnXu, RongdaMultani, Pratik S.Maneval, Edna ChowFriedman, Lori
- [29] Mitazalimab (CD40 agonist) in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Safety data and recommended dose for phase 2 (RP2D) from OPTIMIZE-1, a phase 1b/2 study.CANCER RESEARCH, 2022, 82 (22) : 10 - 11Van Laethem, Jean-LucBorbath, IvanPrenen, HansLambert, AurelienGeboes, KarenBlanc, Jean-Fredericde Coana, Yago PicoEnell-Smith, KarinSchultz, LenaNordbladh, KarinEllmark, PeterAmbarkhane, SumeetCarlsson, MalinCassier, Philippe
- [30] A phase I dose-escalation study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)LoRusso, PatriciaGounder, Mrinal M.Patel, Manish R.Yamamoto, NoboruBauer, Todd MichaelLaurie, ScottGrempler, RolfDavenport, TeffanyGeng, JunxianRohrbacher, MarenLahmar, Mehdi